A Single-Center, Randomized, Investigator/Subject-Blind, Single Dose, Placebo-Controlled, Parallel Group Study to Investigate the Pharmacodynamic and Pharmacokinetic Behavior of RO5508887 in Plasma and Cerebral Spinal Fluid Following Oral Administration in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 11 Jun 2016
At a glance
- Drugs RG 7129 (Primary)
- Indications Alzheimer's disease
- Focus Biomarker; Pharmacodynamics
- Sponsors Roche
- 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 May 2012 New trial record
- 01 May 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.